Scott A. Allen, MD; Anne C. Spaulding, MD; Albert M. Osei, MD; Lynn E. Taylor, MD; Asya M. Cabral, MPH; Josiah D. Rich, MD, MPH
Grant Support: Dr. Josiah D. Rich is partially supported by grant P30-AI-42853 from the National Institutes of Health Center for AIDS Research (NIH CFAR).
Requests for Single Reprints: Josiah D. Rich, MD, MPH, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906; e-mail, firstname.lastname@example.org.
Current Author Addresses: Drs. Allen, Spaulding, Osei, and Cabral: Rhode Island Department of Corrections, 39 Howard Avenue, Cranston, RI 02920.
Drs. Taylor and Rich: The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906.
Author Contributions: Conception and design: S.A. Allen, A.C. Spaulding, A.M. Osei, J.D. Rich.
Analysis and interpretation of the data: S.A. Allen, A.C. Spaulding, A.M. Osei, L.E. Taylor, J.D. Rich.
Drafting of the article: S.A. Allen, A.C. Spaulding, L.E. Taylor, J.D. Rich.
Critical revision of the article for important intellectual content: A.C. Spaulding, A.M. Osei, L.E. Taylor, J.D. Rich.
Final approval of the article: S.A. Allen, J.D. Rich.
Provision of study materials or patients: S.A. Allen.
Administrative, technical, or logistic support: A.C. Spaulding, A.M. Cabral.
Collection and assembly of data: S.A. Allen, A.C. Spaulding, A.M. Cabral.
Allen S., Spaulding A., Osei A., Taylor L., Cabral A., Rich J.; Treatment of Chronic Hepatitis C in a State Correctional Facility. Ann Intern Med. 2003;138:187-190. doi: 10.7326/0003-4819-138-3-200302040-00010
Download citation file:
Published: Ann Intern Med. 2003;138(3):187-190.
Approximately 1 in 4 of the nearly 2 million individuals in state and federal correctional facilities are infected with hepatitis C virus (HCV). Currently, there are few reports of treatment outcomes of this common infection in this setting.
To describe HCV therapy in the incarcerated setting.
Retrospective, descriptive observational study.
Rhode Island Department of Corrections, Cranston, Rhode Island.
93 inmates with chronic HCV infection.
Interferon- with ribavirin.
HCV RNA levels 6 months after treatment.
Response rates are similar to previously published rates achieved in the community; 63% (50 of 79) of patients achieved viral clearance after 6 months of therapy, and 46% (26 of 57) achieved sustained response 6 months after treatment.
The incarcerated population (which is disproportionately affected by addiction and psychiatric illness) can be effectively treated for HCV infection with interferon and ribavirin. The correctional setting may provide an opportunity to safely treat patients with these two challenging comorbid conditions.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Infectious Disease, Liver Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only